2023-12-21 11:18:41 ET
More on BioAtla
- BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on BioAtla
For further details see:
BioAtla CEO purchases 50K common shares2023-12-21 11:18:41 ET
For further details see:
BioAtla CEO purchases 50K common sharesMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
BioAtla Inc. Company Name:
BCAB Stock Symbol:
Market:
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 Evalstotug (CTLA-4 antibody) Phase 1 stud...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developmen...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...